Can Sideroblastic Anemia Present Later in Life?
Yes, sideroblastic anemia can definitely present later in life, including in middle-aged and elderly adults, through both acquired forms and late-manifesting genetic variants.
Acquired Sideroblastic Anemia in Older Adults
The most common form of sideroblastic anemia presenting in older adults is myelodysplastic syndrome with ring sideroblasts (MDS-RS), which is a clonal disorder that typically affects elderly patients 1. This represents the most frequent acquired form of sideroblastic anemia and is fundamentally different from congenital forms 2, 3.
Key Clinical Scenarios for Late Presentation:
Elderly patients with MDS-RS: When elderly patients present with refractory anemia with ring sideroblasts or refractory cytopenia with multilineage dysplasia (especially if microcytic), ALAS2 genetic defects should still be considered even though MDS is more likely 1
Post-infectious sideroblastic anemia: Transient acquired sideroblastic anemia can occur as a delayed manifestation following infections, as documented in a 57-year-old patient who developed severe sideroblastic anemia three months after COVID-19 infection 4
Reversible toxic/metabolic causes: Acquired sideroblastic anemia can develop at any age from medications, alcohol, copper deficiency, or other reversible causes 3, 5
Late-Manifesting Genetic Forms
Female carriers of X-linked sideroblastic anemia (XLSA) can develop clinical phenotype later in life 1. This is a critical pitfall that clinicians often miss:
Women who are carriers of ALAS2 mutations (the most common genetic form) may remain asymptomatic for decades due to X-chromosome inactivation patterns 1
Guidelines explicitly recommend screening female carriers because "women may develop an XLSA phenotype later in life" 1
XLSA should be considered "in patients of both gender and of all ages" with microcytic sideroblastic anemia 1
Diagnostic Approach for Late-Onset Presentation
When evaluating middle-aged or older adults with newly diagnosed sideroblastic anemia:
First, exclude acquired/reversible causes 3, 5:
- Medication review (chemotherapy, antibiotics, immunosuppressants)
- Alcohol use assessment
- Copper and zinc levels
- Heavy metal toxicity screening
Second, evaluate for clonal disorders 1:
- Bone marrow examination with cytogenetics
- SF3B1 mutation testing (present in most MDS-RS cases)
- Assessment for dysplasia and other MDS features
Third, consider genetic testing even in older adults 1:
- ALAS2 gene sequencing, particularly if anemia is microcytic
- Especially important in women with family history
- Consider if MDS features are absent despite ring sideroblasts
Important Clinical Pitfalls
Do not assume all sideroblastic anemia in elderly patients is MDS 1. The guidelines specifically warn that elderly patients presenting with apparent MDS-RS without specific cytogenetic abnormalities should be evaluated for ALAS2 defects, particularly when the anemia is microcytic rather than the typical macrocytic pattern of MDS 1.
Screen family members of any newly diagnosed case regardless of patient age 1. Female relatives may be at risk for late manifestation, and male relatives may have undiagnosed disease 1.
Treatment Implications for Late-Onset Cases
Management depends on the underlying cause 6, 5:
For genetic XLSA diagnosed late: Trial of pyridoxine 50-200 mg daily (up to 300 mg in elderly patients), with monitoring for iron overload and hepatic complications 1
For MDS-RS: Supportive care with consideration of luspatercept (erythroid maturation agent) for anemia management 6, 5
For reversible causes: Address the underlying etiology (discontinue offending medications, treat copper deficiency, etc.) 3, 5
Iron overload management: Monitor ferritin and transferrin saturation; treat with phlebotomy (if tolerated) or chelation therapy depending on severity and transfusion burden 1, 5